STOCK TITAN

Biogen Inc Stock Price, News & Analysis

BIIB Nasdaq

Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.

Biogen Inc (BIIB) delivers pioneering therapies for neurological disorders through cutting-edge biotechnology research. This page aggregates all official announcements, regulatory developments, and strategic updates directly from the company and verified sources.

Investors and healthcare professionals will find timely updates on clinical trial results, FDA approvals, earnings reports, and research partnerships. Track Biogen's progress in Alzheimer's disease treatments, multiple sclerosis therapies, and rare condition solutions through curated press releases and analysis.

Our news hub simplifies monitoring Biogen's pipeline advancements and market position. Key content includes product launch details, executive leadership changes, collaboration announcements, and financial performance data. All information is organized chronologically for efficient research and decision-making.

Bookmark this page for streamlined access to Biogen's latest developments in neuroscience innovation. Verify publication dates and consult original SEC filings for complete context on all disclosed information.

Rhea-AI Summary

Eisai has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for LEQEMBI (lecanemab-irmb) subcutaneous autoinjector for weekly maintenance dosing for early Alzheimer's disease. The BLA leverages data from the Clarity AD Study 301 and aims to allow home or medical facility administration, reducing the need for hospital visits compared to IV administration. LEQEMBI has gained approval in the U.S., Japan, and China, with more submissions pending globally. Concerns include amyloid-related imaging abnormalities (ARIA), which can cause serious side effects. Ongoing studies include AHEAD 3-45 and Tau NexGen for preclinical and dominantly inherited Alzheimer's, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
-
Rhea-AI Summary

Biogen Inc. (Nasdaq: BIIB) released its 2023 Corporate Responsibility Report, highlighting progress in key areas such as access to medicines, workforce diversity, community impact, and environmental sustainability. The report showcases achievements like adding new medicines to the portfolio, expanding access to treatments, increasing workforce diversity, supporting local communities, and enhancing environmental initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none

FAQ

What is the current stock price of Biogen (BIIB)?

The current stock price of Biogen (BIIB) is $144.87 as of September 17, 2025.

What is the market cap of Biogen (BIIB)?

The market cap of Biogen (BIIB) is approximately 21.1B.
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

BIIB Stock Data

21.07B
146.36M
0.15%
92.56%
3.22%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE